Get the Weekly Intelligence Brief — top committee picks every Sunday.

SYRE vs TECH

Spyre Therapeutics, Inc. vs Bio-Techne — AI-powered side-by-side comparison
SYRE
Spyre Therapeutics, Inc.
72
Buy
VS
TECH
Bio-Techne
71
Buy
MetricSYRETECH
AI Score 72 71
Price $103.56 $72.42
P/E Ratio -53.14× 61.88×
ROE -21.7% 8.5%
Revenue Growth YoY
Gross Margin 0.0% 65.8%
Debt / Equity 0.00× 0.13×
Dividend Yield 0.0% 0.4%
RSI (14) 54.6 63.6
Beta 3.026 1.277
Expected Upside

AI Committee View

Current Innellis committee reasoning for SYRE versus TECH.
SYRE leads by 1 points.

SYRE scores 72/100 (Buy) versus TECH at 71/100 (Buy).

SYRE Committee View
100% agreement
4 analysts

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
TECH Committee View
80% agreement
5 analysts

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
  • Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
SYRE Full Analysis TECH Full Analysis